Cellartis AB is pleased to announce the successful completion of a financing round led by a new investor, Bio Fund Management Ltd of Finland (BioFund). Existing shareholders, InnovationsKapital, Catella Healthcare Investments, T-bolaget, Texcel and Barnwik AB, also participated in the financing round. “The financing will allow Cellartis to accelerate the development of different human cell types for use in drug discovery, as well as toxicological testing, and generate GMP grade cells in large quantities necessary for several applications, including, longer term, regenerative medicine. Moreover, the financing will provide the start of Cellartis international expansion”, said Mats Lundwall, CEO of Cellartis.
